– Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases
– Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence site activation to begin enrollment this month
– Company advancing Alzheimer’s Disease Phase 2 asset towards investigational new drug application (IND) filing anticipated in H2 2021
Cyclo Therapeutics, Inc. (NASDAQ:CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced the launch of its new corporate website, cyclotherapeutics.com.
